http://www.biospace.comBioSpace RSS GeneratorWed, 19 Jun 2013 07:40:32 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.chinabiotoday.com/articles/20130502_2Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>by Richard Daverman, PhD</p><p>May 2, 2013 -- Zhejiang Huahai Pharma will offer 63.3 million shares at a price of 12.25 RMB each, raising 775 million RMB ($126 million) in a secondary offering. It...Fri, 03 May 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130422_1by Richard Daverman, PhD</p><p>April 22, 2013 -- Syros Pharmaceuticals, a Boston area startup, raised $30 million to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding, which was led by ARCH Venture Partners and Flagship Ventures. More details....</p><p>Stock Symbol...Tue, 23 Apr 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121116Suzhou, China, November 16, 2012 / B3C newswire / - Innovent Biologics, Inc., a company dedicated to the development and manufacturing of monoclonal antibodies to be marketed in the rapidly growing China market and elsewhere around the world, has raised $25 Million in a Series B financing to put toward the continued expansion of its pipeline and manufacturing capabilities. The money comes from Lilly...Fri, 16 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=276870&full=1REHOVOTH, Israel--(BUSINESS WIRE)-- Pharma Two B Ltd., a privately held company focused on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, announced that it has completed its second round of financing and has raised $8 million.</p><p>Financing will be used to continue the development of the company's Fixed-Dose-Combination product for the...Tue, 23 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=271667&full=1PARIS THERAVECTYS, a biotechnology company that is developing a new generation of vaccines based on lentiviral vector technology (*), announced today that it has secured 7.48 million euros as of the end of H1 2012. These funds, raised exclusively from private investors, will enable THERAVECTYS to pursue the development of a new generation of vaccines, with an anti-HIV therapeutic vaccine as first...Tue, 04 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=264428&full=1Nijmegen, The Netherlands, June 19, 2012 Xenikos BV (Xenikos) has completed a EUR 3.6 million Series A financing round with strategic partner Sanquin Blood Supply Foundation (Sanquin), Participatiemaatschappij Oost Nederland N.V., and Innovation & Investment Fund Gelderland B.V. In addition, Xenikos has secured a EUR 1.9 million Innovation Credit granted by Agentschap NL, an agency...Tue, 19 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=262574&full=1Lyon, France, June 4, 2012 - Alize Pharma, a group of companies developing drugs for the treatment of metabolic diseases and cancer, announces today that it has completed a funding round of EUR 3.3 million. The funds will allow to take AZP-531, its UAG (UnAcylated Ghrelin) analog, into Phase I clinical trials.</p><p>Alize Pharma will carry out the first (Phase I) clinical trial of AZP-531 in healthy...Mon, 04 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=255510&full=1Les LABORATOIRES NUTRITION & CARDIOMETABOLISME, expert in medical nutrition and metabolic diseases, announced the successful completion of their second funding round totaling 3.5 m. This round was led by Seventure Partners accompanied by a group of investors from South-Western France (IRDI, GSO Capital, Aqui-Invest) and LNCs historical shareholder EPI. </p><p>LNC designs and develops...Wed, 04 Apr 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/112205/promethera-raises-236-million-euros-with-backers-including-shire-and-boehringer.htmlBelgian cell therapy firm Promethera Biosciences raised 23.6 million (about $31.4 million) in a Series B round of financing. The funds come in the form of 17 million in capital from a group of five new investors, and a 6.6 million loan from the regional Walloon investment body, which has backed Promethera since its establishment in 2009. Promethera is a spin-out from the Universit Catholique de...Thu, 29 Mar 2012 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/celtic-pledges-50m-to-establish-adc-therapeutics/81246545/NEW YORK & LAUSANNE, Switzerland & LONDON--(BUSINESS WIRE)-- Celtic Therapeutics Management L.L.L.P. the global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products, with the launch of a new Switzerland-based company. ADC Therapeutics Sarl (ADC Therapeutics) has been formed with a pipeline of ten proprietary...Mon, 26 Mar 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=254032&full=1Paris, March 22, 2012 Enterome, a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), today announces a first closing of a series A funding round, raising EUR five million. This funding follows a previous seed round that raised EUR 1.5 million from...Thu, 22 Mar 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=249595&full=1Mumbai, India, February 14, 2012: Fidelity Growth Partners India (FGPI) has led a round of investment of approximately $40M in Hyderabad-based Aptuit Laurus Private Limited (Laurus), a company that develops and manufactures active pharmaceutical ingredients (APIs). </p><p>Dr. Chava Satyanarayana, founder and CEO of Laurus, also participated in this round of financing. </p><p>Laurus is a leading...Tue, 14 Feb 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=247334&full=1MANCHESTER, England, <span class"xn-chron">Jan. 25, 2012</span> /PRNewswire/ -- CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today announced it has raised a Series A financing round led by Advent Life Sciences. The financing raised 2 million pounds, equivalent to approximately US <span class"xn-money...Wed, 25 Jan 2012 12:00:00 AM GMThttp://biofuelsdigest.com/bdigest/2012/01/23/lanzatech-raises-58m-in-series-c-round-petronas-becomes-strategic-investor/Malaysias national oil company invests in early-stage advanced biofuels venture. Is SE Asia the next stop for LanzaTechs magic microorganism? In Illinois, LanzaTech announced that it has closed its Series C round with new investment totaling US $55.8 million led by the Malaysian Life Sciences Capital Fund. New investors include Petronas Technology Ventures Sdn Bhd, the venture arm of Petronas, the...Mon, 23 Jan 2012 12:00:00 AM GMThttp://www.xconomy.com/boston/2012/01/18/rana-raises-20-7m-from-atlas-sr-one-monsanto-for-rna-based-tech/CAMBRIDGE, Mass.--(BUSINESS WIRE)-- RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. The company is developing a technology platform to enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called...Wed, 18 Jan 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=245668&full=1BERGEN, Norway--(BUSINESS WIRE)-- BerGenBio AS, an emerging oncology biopharma company, today announced it has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic. Lead investors are Sarsia Seed AS and Investinor AS. </p><p>BerGenBio CEO Richard Godfrey commented: This significant...Mon, 09 Jan 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20111212005478&newsLang=enAUSTIN, Texas--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a biopharmaceutical company developing the G-Pen, a glucagon rescue pen for emergency treatment of severe hypoglycemia, has completed a Series A preferred stock financing for approximately $1.5 million. The financing was led by the Central Texas Angel Network (CTAN), with significant participation of life science investors including family...Mon, 12 Dec 2011 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/oxyrane-raises-26-5m-to-take-lead-enzyme-replacement-therapy-through-phase-i-ii/81245966/Naarden, The Netherlands, 17 November 2011 - Forbion Capital Partners today announces that it has invested in Oxyrane UK Limited, a biopharmaceutical company dedicated to the development of enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than forty rare inherited diseases. In its oversubscribed Series D financing round the company raised $26.5m. Other investors...Thu, 17 Nov 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=235394&full=1Manchester, UK. 4th October 2011 --Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a 7 million Series B funding round designed to accelerate the companys development plans.</p><p>The investment is led by Inventages, one of the worlds largest life science funds specialised in treatment solutions for chronic diseases...Tue, 04 Oct 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=234253&full=1ORANGE COUNTY, Calif. & LONDON--(BUSINESS WIRE)-- Dr Kary Mullis, the Nobel Prize-winning inventor of the Polymerase Chain Reaction (PCR), the cornerstone of much of todays DNA science, has entered a new joint venture with Loxbridge Research LLP to form Altermune Technologies LLC, focused on the development of novel therapeutics to combat resistant pathogens such as MRSA, C. difficile, pseudomonas...Thu, 22 Sep 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20110920<div id"releaseBody"><p>SHANGHAI, CHINA--(Marketwire - September 20, 2011) - Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors, including ARCH Venture Partners, Fidelity Biosciences, Fidelity Growth Partners Asia...Tue, 20 Sep 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=232383&full=1Copenhagen, Denmark - September 7, 2011; Orphazyme ApS, a biopharmaceutical company which develops innovative treatments for a family of genetic disorders called lysosomal storage diseases, today announced the successful completion of a 14 million Series A financing round. Participants were new investor Aescap Venture, as well as existing investors Novo A/S, and Sunstone Capital. In conjunction with...Wed, 07 Sep 2011 12:00:00 AM GMThttp://www.pmlive.com/find_an_article/allarticles/categories/General/2011/september_2011/news/amakem_raises_18m_for_glaucoma_treatmentBelgium</span>, <span class"xn-chron">September 6, 2011</span> /PRNewswire/ --</p><br /><p style"text-align: center"><u><b>'Localized Drug Action' platform generates novel kinase inhibitors for eye conditions including glaucoma</b></u></p><p style"text-align: center"> </p><p>Amakem NV today announced it has raised 18m with a syndicate of leading life sciences investors to advance its ophthalmology...Tue, 06 Sep 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=230912&full=1SOUTHAMPTON, England, August 23, 2011 /PRNewswire/ --</p><p>KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised 8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.</p><p>The Company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach...Tue, 23 Aug 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=228229&full=1Heidelberg, Germany -- Novaliq GmbH a drug delivery company with focus on technologies for poorly soluble drugs for ophthalmic and topical applications has today announced the successfully completion of a financing round of 2.3 Mio. Since its foundation in the year 2004 the company has raised 9,3 Million in three finance rounds. </p><p>Investor is again the investment company of SAP...Wed, 27 Jul 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20110709July 8, 2011 -- BeiGene, the Beijing area oncology startup, said it expects to raise between $100 million and $150 million this year from a group of up to seven biopharmas and venture capitalists. In May, the company announced it received backing from Merck, though it didnt disclose the size of the financing. At the time, CEO John Oyler told ChinaBio Today that the Merck financing did not prohibit...Mon, 11 Jul 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=223982&full=1Utrecht, The Netherlands, June 14, 2011. Cristal Delivery B.V. is a new nanomedicine company that creates clear value for patients in areas of unmet medical needs. Cristal Deliverys nanoparticulate drug delivery platform increases efficacy, safety and convenience of pharmaceutical products through tuneable and controlled drug release inside the body. Cristal Delivery is developing a proprietary product...Tue, 14 Jun 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=210073&full=1PARIS, February 9, 2011 /PRNewswire/ -- Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.</p><p...Wed, 09 Feb 2011 12:00:00 AM GMThttp://www.pehub.com/95147/pharma-co-altacor-closes-3m-tranche/CAMBRIDGE, England, February 8, 2011 /PRNewswire/ -- Altacor today announced the closing of the second tranche (GBP1.9m) of a GBP3.4m equity fund raising which was led by Clive Austin of NVM Private Equity and included Enterprise Ventures (through its RisingStars Growth Fund) and Beringea, an existing investor. The first tranche which closed in the autumn 2010 was led by Esperante and included The...Wed, 09 Feb 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=202253&full=1<div id"releaseBody"><p>ZURICH-SCHLIEREN, SWITZERLAND--(Marketwire - November 12, 2010) - <p><br>Delenex Therapeutics AG, aSwiss biotech company developing therapeutic antibody fragments targetingserious medical diseases with high unmet need, has announced the closing ofitsSeries A venture equity investment round securing CHF 13.5 million (USD 14million, EUR 10 million).<p>The...Fri, 12 Nov 2010 12:00:00 AM GMThttp://www.unquote.com/dach/news/1811325/index-invests-eur10m-mind-nrgGenetic Engineering News -- Index Ventures has pledged to provide up to a 10 million (about $14 million) investment in Mind-NRG, a newly incorporated Swiss CNS therapeutics firm. The new company is focused on the development of a peptidic neurotrophic factor candidate NRG-101, which it claims has disease-modifying potential and can cross the blood-brain barrier by receptor-mediated transport to reach...Wed, 27 Oct 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=196550&full=1Cambridge, UK, 4 October 2010. Convergence Pharmaceuticals Ltd, a new company focused on the development of novel and high value analgesic medicines, was officially launched today and has successfully raised $35.4 million (22.4 million) in Series A financing from a syndicate of leading European and US life science investors. Convergence Pharmaceuticals is an independent biotechnology company...Tue, 05 Oct 2010 12:00:00 AM GMThttp://www.prnewswire.com/news-releases/eddingpharm-cayman-inc-announces-closing-of-series-b-funding-103122219.htmlWANCHAI, Hong Kong, Sept. 17 /PRNewswire/ -- Eddingpharm (Cayman) Inc., a leading specialty pharmaceutical marketing company focused on the China market, today announced the closing of a US$24 million Series B financing, co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Sequoia Capital China Growth Fund also participated in the financing. The financing will be used primarily...Fri, 17 Sep 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=187087&full=1UK: 12 July 2010. Kymab and The Wellcome Trust investment division announced today a 20 million Series A equity financing. Kymab is a biopharmaceutical company focused on the discovery, development and commercialisation of novel monoclonal antibody medicines. The company is a spin-out from The Wellcome Trust Sanger Institute, Cambridge, a world leader in the Human Genome Project and genetic studies...Tue, 13 Jul 2010 12:00:00 AM GMThttp://www.pharmatimes.com/ClinicalNews/article.aspx?id=18181Pharma Times -- The Wellcome Trusts investment division has agreed a 20 million Series A equity financing for Kymab, a biopharmaceutical company spun out from the Trusts Sanger Institute in Cambridge, UK and focused on the discovery, development and commercialisation of novel antibody-based medicines.Tue, 13 Jul 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=186518&full=1<div id"releaseBody"><p>LYON, FRANCE--(Marketwire - July 08, 2010) - Poxel S.A. / Poxel Raises EUR16 million in aSeries A Financing to Accelerate Pipeline Development processed andtransmitted by Hugin AS. The issuer is solely responsible for the contentof this announcement.<p>Lyon, France, July 8, 2010 - Poxel SA, a diabetes drug developmentspecialist,announces today that it...Thu, 08 Jul 2010 12:00:00 AM GMThttp://www.pehub.com/73806/belgium-based-complix-raises-e5-million/PeHub -- Complix NV, a Belgium-based developer of alphabodies for autoimmune and infectious diseases, has raised 5 million in Series A funding. Backers include Vesalius Biocapital, LRM and CRP Sant.Wed, 09 Jun 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=181911&full=1CAMBRIDGE, England--(BUSINESS WIRE)--Funxional Therapeutics Ltd announced today the completion of a Series B financing round in which it raised a total of EUR 10 million (US$ 12.5 million). Ventech participated as a new investor in this round, together with existing investors Index Ventures and Novo A/S.</p><p>The capital raised enables Funxional Therapeutics to further progress the development...Wed, 26 May 2010 12:00:00 AM GMThttp://www.masshightech.com/stories/2010/05/10/daily45-Caprotec-bioanalytics-closes-5M-funding-round.html<div class"xn-content"><p><span class"xn-location">BERLIN</span>, and <span class"xn-location">BURLINGTON, Mass.</span>,<b></b><span class"xn-chron">May 13</span> /PRNewswire/ -- caprotec bioanalytics GmbH today announced the closing of a <span class"xn-money">EUR 4 million</span> (<span class"xn-money">$5.1M</span>) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft...Fri, 14 May 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=178279&full=1S-HERTOGENBOSCH, The Netherlands, April 27, 2010 /PRNewswire/ -- Immunovo BV, a new biotechnology company looking to combine novel methods in immunotherapy with the most recent insights in oncology to develop novel therapeutics, secures seed funding from Dutch venture capital firms.</p><p>'S-Hertogenbosch, The Netherlands, April 27, 2010 - Immunovo BV, a new biotechnology company developing a novel...Wed, 28 Apr 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=176149&full=1 LAUSANNE, Switzerland, April 8, 2010 /PRNewswire/ -- Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD...Thu, 08 Apr 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=172488&full=1Davis, CA March 1, 2010 Gold Standard Diagnostics, Inc. (GSD) today announced the completion of its Series A round of private financing.<p></p>The funding was led by a group of private investors including Roger Salquist. Well known for his local, biotech entrepreneurship, Salquist has more than 35 years experience as a senior executive in the Life Sciences Industry. In connection with the Series...Tue, 02 Mar 2010 12:00:00 AM GMThttp://www.washingtonexaminer.com/local/Biotech-startup_-pushed-by-chairman_-lands-millions-in-public-funds-84400057.htmlWashingtno Examiner -- Montgomery County officials gave a Gaithersburg company a $1.5 million taxpayer-funded grant based on support for the startup by a venture capitalist who leads it.Tue, 16 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169790&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Thu, 04 Feb 2010 12:00:00 AM GMThttp://www.pehub.com/62185/dutch-biotech-merus-raises-e217-million/<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 29 Jan 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161216&full=1VIENNA, AUSTRIA, October 30, 2009 / b3c newswire / - PDC Biotech GmbH (PDC) today announced the close of a Series A financing of over 4 million. MIG Verwaltungs AG (Munich) and Edmond de Rothschild Investment Partners (Paris) co-led the round.</p><p>Proceeds from the financing will be used to complete preclinical work and the first clinical study of the companys lead compound, PDC31 which is...Fri, 30 Oct 2009 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20090912005007&newsLang=enPARIS--(BUSINESS WIRE)--FAB Pharma today announced the completion of a 2.3 million round of series A funding led by CDC innovation and co-led by Bioam Gestion.Mon, 14 Sep 2009 12:00:00 AM GMThttp://www.pehub.com/42591/swiss-biopharma-lumavita-extends-series-a-round/pehub.com -- Lumavita AG, a Swiss developer of anti-infectives for womens health, has raised CHF 6 million ($5.53m) in new Series A funding. The round total is now CHF 24 million ($22m). HealthCap led the tranche, and was joined by return backer Endeavour Vision.Fri, 19 Jun 2009 12:00:00 AM GMThttp://industry.bnet.com/pharma/10002054/job-market-brutal-but-good-biotech-entrepreneurs-still-hard-to-find/BNET -- Layoffs due to restructuring, mergers, acquisitions and even bankrupties are flooding the biotech job market with talent, but venture capitalists say finding great entrepreneurs is still the hardest part of their job.Thu, 14 May 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=127534&full=1 LONDON, February 24 /PRNewswire/ -- Heptares Therapeutics Ltd, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), announces today it has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor...Tue, 24 Feb 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=127296&full=1February 20, 2009 Munich, Germany - Ascenion GmbH announces today that it is taking an equity position in MBiotec GmbH, a biopharmaceutical company that has recently been founded in order to develop and commercialize the compound MALP-2S for the treatment of cancer. MALP-2 is a lipopeptide originating from mycoplasma that was discovered by Prof. Mhlradt and his team at the Helmholtz Centre for Infection...Fri, 20 Feb 2009 12:00:00 AM GMThttp://www.pehub.com/28812/hs-lifesciences-ag-creates-bio-tech-investment-fund/BioWorld -- The team behind two recent successful start-ups, U3 Pharma AG and NeurImmune Therapeutics AG, is applying the lessons learned from those ventures to a new investment fund and has already completed its first deal, a CHF10 million (US$8.9 million) Series A round in start-up firm CT Atlantic AG. Fri, 16 Jan 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=113170&full=1Exploit Technologies and the Business Angels Network South East Asia (BANSEA)today announced a strategic collaboration under the Exploit Technologies AngelInvestment Management initiative (AIM) to enhance and accelerate angelnetworking activity, and to enable start-ups to have greater access to Angel investorsin Singapore and in the region.</p><p>Under the new partnership, Exploit Technologies...Wed, 15 Oct 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=111362&full=1Lugano-Bioggio, Switzerland, Sept 30, 2008. Telormedix SA, a leader in novel immunotherapeutic molecules , has announced the closing of its first Series A equity investment round raising 21 Mio CHF (13.1 million, $19 million), one of the largest Series A round in Switzerland for a biotech company in 2008. The round was supported by an international syndicate of investors, led by Aravis Venture (Basel...Tue, 30 Sep 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=110449&full=1HENNIGSDORF/BERLIN, GERMANY, Monday, September 22, 2008 Revotar Biopharmaceuticals AG today announced the successful closing of its Series A financing round of 5.3 million EUR. Initially, the new investor IBG Risikokapitalfond I, which is managed by Goodvent Beteiligungsmanagement GmbH & Co KG, was joined by Deutsche Life Sciences GmbH and MVC Unternehmensbeteiligungsgesellschaft mbH. In a second...Mon, 22 Sep 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=108609&full=1Investment by GBS Venture Partners, Brandon Capital and Uniseed First A$6m Tranche Received, Second at Phase II Phase II Trial Targeted for 2009 </p><p>MELBOURNE, Australia, September 3, 2008 - Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital...Wed, 03 Sep 2008 12:00:00 AM GMThttp://www.pehub.com/article/articledetail.php?articlepostid=14273Profex Inc., a Shanghai, China-based dermatology startup, has raised $15.5 million in Series A funding. The round was co-led by Trident Capital and its Chinese affiliate Mustang Ventures.Thu, 28 Aug 2008 12:00:00 AM GMThttp://www.pehub.com/article/articledetail.php?articlepostid=13967CAMBRIDGE, England--(BUSINESS WIRE)--Serentis, a privately owned biopharmaceutical company, announced today that it has closed a 10 million ($20 million) financing, expanding the total of its Series A financing to 15.3 million ($30 million). The funding will be used to advance and expand Serentis dermatology pipeline.</p><p>In July 2007, Serentis announced a 10.3 million Series A financing...Tue, 12 Aug 2008 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20080808SHANGHAI, China--(BUSINESS WIRE)--HD Biosciences Inc., a China-based biology contract research organization (CRO) today announced the closing of its Series A financing. The current round was co-led by Morningside Venture and Lilly Asian Ventures and syndicated with Pfizer Venture Investments.Fri, 08 Aug 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=103131&full=1Martinsried/Munich, Germany, July 14, 2008 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that it has closed a EUR 15.7 million Series B financing round. Lead investors are MIG AG (Munich, Germany), and BioMedInvest AG (Basel, Switzerland). Santo Holding GmbH (Stuttgart, Germany) and the existing...Mon, 14 Jul 2008 12:00:00 AM GMT